Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
2.690
+0.150 (5.91%)
At close: Aug 22, 2025, 4:00 PM
2.550
-0.140 (-5.20%)
After-hours: Aug 22, 2025, 7:59 PM EDT
Iovance Biotherapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Iovance Biotherapeutics stock have a consensus rating of "Buy" and an average price target of $11.9, which forecasts a 342.38% increase in the stock price over the next year. The lowest target is $2.00 and the highest is $20.
Price Target: $11.9 (+342.38%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Buy | 2 | 3 | 3 | 3 | 3 | 4 |
| Hold | 1 | 1 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 10 | 10 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +643.49% | Aug 19, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $18 → $14 | Buy | Maintains | $18 → $14 | +420.45% | Aug 8, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 → $20 | Strong Buy | Maintains | $25 → $20 | +643.49% | Aug 8, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +829.37% | Jul 23, 2025 |
| UBS | UBS | Strong Buy → Hold Downgrades $17 → $2 | Strong Buy → Hold | Downgrades | $17 → $2 | -25.65% | May 16, 2025 |
Financial Forecast
Revenue This Year
306.19M
from 164.07M
Increased by 86.62%
Revenue Next Year
517.87M
from 306.19M
Increased by 69.13%
EPS This Year
-1.16
from -1.28
EPS Next Year
-0.77
from -1.16
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 499.0M | 762.4M | 1.2B | ||
| Avg | 306.2M | 517.9M | 727.3M | ||
| Low | 245.7M | 367.5M | 465.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 204.1% | 149.0% | 138.9% | ||
| Avg | 86.6% | 69.1% | 40.4% | ||
| Low | 49.7% | 20.0% | -10.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.96 | -0.38 | 0.08 | ||
| Avg | -1.16 | -0.77 | -0.22 | ||
| Low | -1.25 | -1.02 | -0.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.